PR Newswire (press release)transOMIC technologies Unveils transEDIT-dual CRISPR Arrayed LibraryPR Newswire (press release)HUNTSVILLE, Ala., March 7, 2017 /PRNewswire/ — Unlike other CRISPR/Cas9 vector-based systems, the transEDIT-dual vector system ex… Continue reading
Yahoo FinancetransOMIC technologies Unveils transEDIT-dual CRISPR Arrayed LibraryYahoo FinanceHUNTSVILLE, Ala., March 7, 2017 /PRNewswire/ — Unlike other CRISPR/Cas9 vector-based systems, the transEDIT-dual vector system expresses two gRNAs from the s… Continue reading
ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two …Yahoo FinanceThese data support the therapeutic strategy of using red blood cells as carriers to induce efficient and antigen-specific immune respo… Continue reading
Key Capital Corporation Announces Immunotherapy Product Rights AgreementYahoo FinanceThe Immunitor V-5 immunotherapy product has recently demonstrated groundbreaking trial success in the treatment of patients with advanced or terminal liver cancer (Hep… Continue reading
ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two …Business Wire (press release)These data support the therapeutic strategy of using red blood cells as carriers to induce efficient and antigen-speci… Continue reading
PLoS Blogs (blog)Synbio for bioremediation: fighting plastic pollutionPLoS Blogs (blog)Plastic pollution is one of the major problems of our times. Plastic is a durable material that can be moulded into solid objects of the most disparate shapes. Prope… Continue reading
Melanoma News TodayMelanoma Gene Study May Help Predict Who Will Benefit from ImmunotherapyMelanoma News TodayWhile high mutation load in metastatic melanoma is often associated with better responses to immune checkpoint inhibitors, researchers have fo… Continue reading
BioPharma-Reporter.com |
Kite public offering looks to raise $350m for CAR T cell therapy support
BioPharma-Reporter.com “We intend to use the net proceeds from this offering to support commercialization activities of axicabtagene ciloleucel, if approved, to support clinical activities related to KTE-C19 and our other CAR– and TCR-based product candidates,” the firm said … |